Pfizer (NYSE: PFE) is in that group, in my opinion. The big drugmaker's forward dividend yield currently stands at just under ...
Haleon backed its full-year guidance despite lower third-quarter revenue and earnings, although organic revenue growth of 6.1% topped its own forecasts.
During the same period, the company received roughly $6.9 billion of net cash proceeds from the sale of its shares of Haleon, a consumer health joint venture with GSK. In Pfizer's Q3 earnings call ...
Haleon backed its full-year guidance despite ... healthcare business--which was spun out of GSK and is partly owned by Pfizer--said Thursday that revenue for the quarter was 2.78 billion pounds ...
We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.
Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...